Current advances in research on adjuvant therapy for cerebral malaria / 药学学报
Acta Pharmaceutica Sinica
; (12): 208-217, 2020.
Article
em Zh
| WPRIM
| ID: wpr-789027
Biblioteca responsável:
WPRO
ABSTRACT
Cerebral malaria (CM) is the deadliest complication of Plasmodium falciparum infection and even with effective anti-malarial treatment the mortality of children can be as high as 18%; up to one-third of CM survivors are left with neurological and cognitive deficits. The pathophysiology of CM is not completely understood, but mechanical obstruction and immunopathology are its mainstream theories. Adjuvant therapy aims to improve clinical outcomes and/or reduce mortality, as well as preventing long-term neurocognitive deficits. Improving survival and reducing neurological damage to survivors are new goals for new antimalarials and adjuvant therapies. Herein, we discussed what is known about the disease mechanism of CM and systematically summarize the progress of adjuvant therapy research in protecting the vascular endothelium, reducing adhesion formation, regulating immune balance, interfering with malarial metabolism, protecting nerves, improving nitric oxide bioavailability, improving energy metabolism and alleviating inflammation, with the aim of exploiting this understanding to reduce the neurological damage to children with CM. This work also highlights some preclinical studies which may be candidate strategies in future clinical trials.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2020
Tipo de documento:
Article